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Coumadin (R/S-warfarin) anticoagulant therapy is highly efﬁcacious in preventing the
formation of blood clots; however, signiﬁcant inter-individual variations in response
risks over or under dosing resulting in adverse bleeding events or ineffective therapy,
respectively. Levels of pharmacologically active forms of the drug and metabolites depend
on a diversity of metabolic pathways. Cytochromes P450 play a major role in oxidizing Rand S-warfarin to 6-, 7-, 8-, 10-, and 4′-hydroxywarfarin, and warfarin alcohols form
through a minor metabolic pathway involving reduction at the C11 position. We
hypothesized that due to structural similarities with warfarin, hydroxywarfarins undergo
reduction, possibly impacting their pharmacological activity and elimination. We modeled
reduction reactions and carried out experimental steady-state reactions with human liver
cytosol for conversion of rac-6-, 7-, 8-, 4′-hydroxywarfarin and 10-hydroxywarfarin
isomers to the corresponding alcohols. The modeling correctly predicted the more
efﬁcient reduction of 10-hydroxywarfarin over warfarin but not the order of the
remaining hydroxywarfarins. Experimental studies did not indicate any clear trends in
the reduction for rac-hydroxywarfarins or 10-hydroxywarfarin into alcohol 1 and 2. The
collective ﬁndings indicated the location of the hydroxyl group signiﬁcantly impacted
reduction selectivity among the hydroxywarfarins, as well as the speciﬁcity for the
resulting metabolites. Based on studies with R- and S-7-hydroxywarfarin, we predicted
that all hydroxywarfarin reductions are enantioselective toward R substrates and
enantiospeciﬁc for S alcohol metabolites. CBR1 and to a lesser extent AKR1C3
reductases are responsible for those reactions. Due to the inefﬁciency of reactions,
only reduction of 10-hydroxywarfarin is likely to be important in clearance of the
metabolite. This pathway for 10-hydroxywarfarin may have clinical relevance as well
given its anticoagulant activity and capacity to inhibit S-warfarin metabolism.
Keywords: anticoagulation, warfarin, hydroxywarfarin, metabolism, modeling, reduction, CBR1, AKR1C3
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INTRODUCTION

anticoagulant response (Lewis et al., 1973). Hydroxywarfarins
and warfarin alcohols may still inhibit VKORC1 (Haque, et al.,
2014) or even inhibit metabolism of the parent drugs (Jones, et al.,
2010c) that may contribute to the overall anticoagulant effect.
Those outcomes will ultimately depend on processes impacting
warfarin metabolite levels. Warfarin hydroxylation introduces an
essential site for glucuronidation leading to elimination of most
hydroxywarfarins (Zielinska, et al., 2007; Bratton, et al., 2012;
Kim, et al., 2019; Pugh, et al., 2018), as glucuronides in patient
urine (Kaminsky and Zhang 1997; Miller, Jones, et al., 2009). 10Hydroxywarfarin is the only primary metabolite that does not
undergo glucuronidation and interestingly, is not eliminated in
the urine as an unmodiﬁed metabolite, so that its elimination
pathway remains unknown.
As an alternative to glucuronidation, we hypothesized that
hydroxywarfarin reduction is an alternate, competing pathway
for elimination of these primary metabolites. For each
enantiomer, this process involves reduction of the C11
carbonyl into two possible alcohols or four for a racemic
substrate mixture. Historically, studies carried out with racwarfarin yielded partially resolvable isomers called alcohol 1
(minor metabolite) and alcohol 2 (major metabolite)
(Alshogran, et al., 2014; Malátkova, et al., 2016). Our previous
study further assessed the role of chirality in warfarin reductive
reactions with authentic standards for all isomers (Barnette, et al.,
2017). We determined that alcohol 1 consisted of two co-eluted
alcohol isomers sharing common chiral orientations (9R-11Rhydroxywarfarin and 9S-11S-hydroxywarfarin), whereas alcohol
2 was the combination of alcohols with mixed chiral centers (9R11S-hydroxywarfarin
and
9S-11R-hydroxywarfarin).
Nevertheless, R-warfarin was more efﬁciently metabolized than
S-warfarin and both reactions resulted mainly in formation of the
S alcohol by CBR1 and AKR1C3 (Malátkova, et al., 2016;
Barnette, et al., 2017). Consequently, rac-warfarin reactions

Coumadin (rac-warfarin) is frequently prescribed in the
prophylaxis of thromboembolism in the setting of atrial
ﬁbrillation, stroke, and many other hypercoagulable
conditions. This anticoagulant effect of warfarin is derived
from the inhibition of vitamin K oxidoreductase complex 1
(VKORC1), which is involved in the recycling of vitamin K
during the maturation of coagulation factors (Ansell, et al.,
2008). Despite its important role in anticoagulant therapy
since the 1950s, warfarin remains underutilized due to its
interindividual unpredictability in dose response and narrow
therapeutic range. Patients have their own response to the
medication routinely tested to optimize dosing and mitigate
the possibility of hemorrhaging (over-dosing) or clotting
(under-dosing); nonetheless, warfarin remains in the top ten
drugs for hospitalizations due to side effects (Wysowski et al.,
2007). A deeper understanding of the underlying causes of
response variation may lead to improved management
strategies for achieving and maintaining an optimal dose,
while simultaneously minimizing possible adverse drug events.
Warfarin therapy entails oral treatments of a racemic mixture
of R- and S-warfarin. Reported R-warfarin levels in patients are
on average 2-fold higher than S-warfarin, however S-warfarin is
thought to be 3–5 times more effective as an anticoagulant than
R-warfarin (Lewis et al., 1974; Jones et al., 2010a; Haque, et al.,
2014; Miller 2010). In addition, warfarin potency is impacted by
its extensive metabolism (Figure 1). Each warfarin enantiomer
undergoes primarily oxidation into 6-, 7-, 8-, and 4′hydroxywarfarins and a pair of 10-hydroxywarfarin isomers.
Minor but relevant, competing pathways are warfarin
reductions into pairs of alcohols (Kaminsky and Zhang 1997;
Jones et al., 2010b; Jones and Miller 2011). Metabolism decreases
levels of the parent drugs but do not necessarily eliminate the

FIGURE 1 | Hydroxywarfarins are the predominant metabolites of warfarin metabolism that may be cleared through a novel carbonyl reduction pathway. Warfarin is
directly metabolized via a major pathway by membrane-bound cytochromes P450 to form hydroxywarfarins and a minor pathway by cytosolic reductases to form
warfarin alcohols (Kaminsky and Zhang 1997; Jones and Miller 2011). Further reduction of the hydroxywarfarin major metabolites by reductases to form hydroxywarfarin
alcohols may also be possible as a secondary reaction.
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Modeling Hydroxywarfarin Reductions

mainly yielded 9S-11S-hydroxywarfarin (alcohol 1, minor
metabolite), and 9R-11S-hydroxywarfarin (alcohol 2, major
metabolite). Given access only to rac-hydroxywarfarins, we
anticipated similar metabolic proﬁles of diastereomeric isomers
from reductive reactions. How the regiospeciﬁcity of warfarin
hydroxylation would impact those subsequent reductive reactions
remained unknown.
We tested then the hypothesized reduction of
hydroxywarfarins through a combination of computational
and experimental in vitro metabolic studies. For a rapid initial
analysis, we predicted the likelihood for warfarin and
hydroxywarfarin reduction at the C11 carbonyl using the
publicly available Rainbow Model for metabolism developed
by our group (Dang, et al., 2020). The model does not
consider chirality but does yield a useful, scalable output for
ranking the likelihood of reactions like reductions to occur. For
experimental studies, we leveraged our previous methodologies
(Barnette, et al., 2017) for characterizing R- and S-warfarin
reduction by human liver cytosolic fractions to assess this
metabolic pathway for 6-, 7-, 8-, 10-, and 4′-hydroxywarfarins.
Isomeric mixtures were necessary for these studies given the lack
of commercial availability of the individual isomers. Initially, we
screened for metabolic activities and characterized the resulting
metabolites by liquid chromatography coupled to mass
spectrometry (LC-MS) to conﬁrm the occurrence of
reductions. We then determined conditions suitable for
steady-state studies and measured reaction kinetics for rac-6-,
7-, 8-, and 4′-hydroxywarfarins along with the 10hydroxywarfarin mix of isomers. We then chromatographically
puriﬁed 7-hydroxywarfarin enantiomers and carried out steadystate studies to explore the impact of chirality toward reductase
selectivity and speciﬁcity during reactions. It was not possible to
carry out similar studies with 10-hydroxywarfarin due to the
presence of chiral centers at positions 9 and 10 (Jones and Miller
2011) leading to four unresolvable isomers. 7- and 10Hydroxywarfarin are metabolites of major metabolic pathways,
and so we identiﬁed possible reductases responsible for their
reduction using inhibitor phenotyping. Taken together, this study
provides insights into the importance of hydroxywarfarin
reduction in vitro and serves as a foundation to further
evaluate the potential impact of this process on maintaining
levels of active metabolites on the anticoagulant response in
patients.

For rapid insights on possible reactions, we predicted
hydroxywarfarin reductions at the C11 carbonyl using our
deep neural Rainbow Model that simultaneously labels sites of
metabolism and classiﬁes them into ﬁve key reaction classes:
stable and unstable oxidations, dehydrogenation, hydrolysis,
and reduction (Dang, et al., 2020). The model was trained on
9674 unique molecules and 20736 human in vitro and in vivo
records, including 1590 reduction reactions, from literaturecurated databases. This powerful tool is available for use free
and online through our secure server at http://swami.wustl.
edu/xenosite/p/phase1_rainbow. For each atom or bond site
on the molecule, the model generates a score from 0 to 1.0, with
higher values corresponding to greater likelihood for a
reaction to occur at that location. This model output is
analogous to a probability and provides a strategy to scale
reaction relative likelihoods. In our case, we used this metric to
rank hydroxywarfarin reductions in comparison to parent
drug warfarin. We could then compare the ﬁndings to those
from experimental kinetic studies, which are more labor and
resource intensive.

Steady-State Reduction of Warfarin and
Hydroxywarfarins by Human Liver Cytosol
Steady-state studies involved a two-stage approach to ﬁrst
identify suitable reaction conditions and then to use them for
determining kinetic proﬁles for reactions. Initially, control
experiments were conducted to determine the optimal
reaction time and protein concentration to ensure steadystate conditions. Hydroxywarfarin stocks were prepared in
methanol solutions. For steady-state kinetic reactions,
hydroxywarfarin aliquots were dried down using an
evaporator under nitrogen using an Organomation
Microvap Nitrogen Evaporator System (Organomation
Associates, Inc., Berlin MA) to remove the carrier solvent.
The residual rac-hydroxywarfarin was then resuspended in
50 mM potassium phosphate buffer pH 7.4 and sonicated for
5 min. HLC150 was added to the substrate to ﬁnal
concentrations of 0.25–1.0 mg/ml protein. The mixture was
incubated for 10 min at 37°C with 350 rpm rotation and then
the reaction was initiated with the addition of 1 mM NADPH.
Reactions were quenched after 10, 20, 40, or 60 min using ice
cold acetonitrile containing 1 µM coumatetryl (ﬁnal) as an
internal standard. Quenched reactions were centrifuged at 5°C
at 2,500 rpm for 15 min with the supernatant transferred to a
96 well half-area plate for injection. Those studies identiﬁed
conditions leading to linear response as a function of time and
protein concentration, 40 min and 1.0 mg/ml protein,
respectively, that were used in subsequent steady-state
kinetic studies. Initial rates were measured for substrate
concentrations
ranging
from
50
to
1,000 µM.
Hydroxywarfarin alcohol initial rates were plotted as a
function of substrate concentration and analyzed by
comparing the ﬁt of the data to the Michaelis-Menten
equation
(hyperbolic
curve)
and
Hill
equation
(nonhyperbolic curve) using GraphPad Prism 9.2

MATERIALS AND METHODS
Materials
Unless otherwise stated, common reagents were ACS grade
and purchased from Sigma-Aldrich. Toronto Research
Chemicals was the source for rac-warfarin and rac-6-, 7-,
8-, and 4′-hydroxywarfarin along with the 10hydroxywarfarin mixed isomers. High Performance liquid
chromatography grade methanol and acetonitrile were
obtained from Thermo Fisher (Pittsburgh, PA). Human
liver cytosol pooled from 150 donors (HLC150) was
purchased from Corning Gentest (Corning, NY).
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(San Diego, CA). The best ﬁt was determined using extra sumof-squares F test.

could then be multiplied by the conversion factor to generate a
response comparable to that for substrate making its
quantitation by inference using substrate ﬂuorescence
possible.

Characterization of Hydroxywarfarin
Metabolites by Mass Spectrometry

Inhibitor Phenotyping to Identify
Reductases Responsible for
Hydroxywarfarin Reduction

For structural characterization, sample reactions were injected
onto a Shimadzu UHFLC equipped with an SPD-10A UV–Vis
(280 nm) and RF-10AXL ﬂuorescence (excitation 280 nm,
emission 650 nm) detectors.
Waters Acquity LC series (Waters-Millipore Corp, Milford,
MA) and analytical separation were achieved on a 2.1 × 50 mm
Hypersil Gold 5 µm column (Thermo Scientiﬁc). Parent
compounds and metabolites were separated using a linear
binary gradient (mobile phase A: water containing 0.1%
formic acid, Mobile phase B: acetonitrile containing 0.1%
formic acid). The ﬂow rate was 0.4 ml/min, and the
gradient was: initial 20% (B), 0–2.0 min 20–40% (B),
2.0–2.75 min 40 to 55% (B), 2.75–3.5 min 55–65% (B), held,
and then returned to 20% (B) at 3.6 min. The total run time was
5.0 min. Subsequent mass spectrometry involved a Quattro
Premier triple quadrupole mass spectrometer (WatersMillipore Corp.), which used electrospray ionization to
interface the LC system. Positive ions were generated using
a cone voltage of 25 V. Product ions were generated using
argon collision induced disassociation at a collision energy of
15 eV while maintaining a collision cell pressure of 1.2 × 10−3
torr. Detection was achieved using MS scan from 100 to
400 m/z for fragments of parent ions, m/z 311.2 for
warfarin alcohols, and m/z 327.2 for hydroxywarfarin alcohols.

As major oxidized warfarin metabolites, rac-7- and 10
hydroxywarfarin attain the highest levels in patients
(Locatelli, et al., 2005; Pouncey, et al., 2018), and thus,
reductases involved in their metabolism may have clinical
relevance. Consequently, we identiﬁed those enzymes using
inhibitors relatively speciﬁc for common cytosolic reductases.
Under steady state conditions established in the control
experiments,
reactions
contained
250 µM
rachydroxywarfarin or warfarin (positive control) along with
either methanol alone (control) or with inhibitor (5% ﬁnal
methanol from carrier solvent). Reactions were conducted
using three different inhibitors to selectively inhibit
individual and classes of cytosolic reductases as discussed
in a previous study (Barnette, et al., 2017) and review
(Malátková and Wsól 2014). We employed concentrations
about 5-fold above reported IC50 values to ensure target
inhibition while minimizing off target effects. We used
ﬂufenamic acid (FFA) at a lower concentration (2 µM) to
more selectively inhibit AKR1C3 and at a high concentration
(10 µM) to inhibit all Aldo-keto reductase family 1C members
(AKR1C). Similarly, indomethacin (IND) at lower
concentration (5 µM) selectively blocks AKR1C3 activity
with only limited effects on CBR1 inhibition, but at a high
concentration (180 µM), indomethacin broadly inhibits all
AKR1C members and Carbonyl Reductase 1 (CBR1).
Lastly, we used 60 µM quercetin to target only CBR1
activity for inhibition.

Quantitative Analysis of Hydroxywarfarin
Alcohol Metabolites
Samples were injected onto a 4.6 × 150 mm Zorbax Eclipse
3.5 µm XDB-C18 column (Agilent) heated to 45°C using a
Shimadzu UHFLC equipped with SPD-10A UV–Vis and RF10AXL ﬂuorescence detectors. Analytes including warfarin,
hydroxywarfarins, reduced metabolites, and coumatetryl
(internal standard) were resolved with an isocratic method
of 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer pH 6.5 and 3:1 methanol:acetonitrile. The
elution of analytes was monitored by absorbance at 325 nm
and ﬂuorescence (excitation: 325 nm, emission: 393 nm). Peak
areas were normalized to internal standard and quantiﬁed by
inference using the substrate response. Due to the absence of
authentic metabolite standards, we inferred their quantitation
based on the corresponding responses. Molecular ﬂuorescence
was more sensitive than absorbance; however, carbonyl
reduction impacted ﬂuorescence but not absorbance based
on initial studies with warfarin and warfarin alcohols.
Consequently, for substrate and metabolite in each reaction,
we calculated the response ratio as the normalized peak area
for the ﬂuorescence response divided by that for absorbance
(Rﬂu/abs). Division of the metabolite response ratio by that for
substrate yielded a conversion factor, i.e., CF  Metabolite
Rﬂu/abs ÷ Substate Rﬂu/abs. Metabolite ﬂuorescence responses

Frontiers in Pharmacology | www.frontiersin.org

RESULTS
Modeling Enabled Ranking of Reduction
Predictions for Hydroxywarfarin Isomers
Warfarin and the hydroxywarfarins were all predicted to
undergo reduction at the C11 carbonyl bond with a
moderate to low likelihood compared to the rest of the
Rainbow Model training set. Figure 2 illustrates the
predicted likelihood for reductive reactions, while the actual
values are reported in Table 1. For comparative purposes, we
normalized model predictions for hydroxywarfarins to warfarin.
That strategy showed that introduction of the hydroxyl group
impacted the predicted reduction of the carbonyl. When the
hydroxyl group was added to the 6, 7, or 8 position on the 4hydroxy-coumarin scaffold, there was a slight decrease in
possible reductions. A signiﬁcant reduction occurred upon
inclusion of a 4′ hydroxyl group on the phenyl group distal
from the site of reduction. By contrast, a hydroxyl group at
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FIGURE 2 | Hydroxywarfarin alcohols with reduction model predictions. Reduction predictions for hydroxywarfarins were made using the Xenosite Rainbow Model
(Dang, et al., 2020). Individual bonds are scored from 0 to 1 with higher scores indicating higher likelihood of reduction and indicated pictorially with color shading from
blue to red. Scores for reduction at the C11 position to form hydroxywarfarin alcohols are shown in Table 1. Asterisks denote chiral centers. All hydroxywarfarins contain
a chiral center at C9 except for 10-hydroxywarfarin, which contains another at position 10.

TABLE 1 | Model predictions for reduction of warfarin and hydroxywarfarin isomers.
Absolute reduction scorea

Relative reduction scoreb

0.204
0.195
0.195
0.195
0.256
0.176

1
0.96
0.96
0.96
1.25
0.86

Warfarin
6-hydroxywarfarin
7-hydroxywarfarin
8-hydroxywarfarin
10-hydroxywarfarin
4′-hydroxywarfarin
a

Output value generated by Xenosite Rainbow Model (Dang, et al., 2020) for reduction reactions.
Relative values calculated by dividing reduction scores by that of warfarin.

b

position 10 for 10-hydroxywarfarin resulted in the highest
likelihood of reduction at the C11 carbonyl group.

differences in these initial rates for rac-warfarin and the
hydroxywarfarins were not the same at 100 and 1,000 μM,
suggesting differences in the respective binding speciﬁcities,
e.g., Km, among reactions. Subsequent LC-MS characterization
provided evidence for the expected metabolite structures, namely,
311 m/z for warfarin alcohols (positive controls) and 327 m/z for
hydroxywarfarin alcohols (Figure 4).

Hydroxywarfarins Underwent Reduction
Into Isomeric Alcohols
Initially, we screened rac-hydroxywarfarins for the potential for
reduction by pooled human liver cytosolic fractions (HLC150)
with rac-warfarin serving as a positive control (Figure 3). Like the
parent drug, rac-hydroxywarfarins underwent metabolism into a
minor metabolite (alcohol 1) followed by a major metabolite
(alcohol 2). Unlike warfarin, the addition of a hydroxyl group
impacted speciﬁcity of reduction rates and their relative values for
alcohols 1 and 2. In fact, the minor alcohol 1 metabolite was not
observable for rac-4′-hydroxywarfarin reactions. In general, rac10-hydroxywarfarin underwent the highest rates of reduction for
both alcohols followed by warfarin and 6-hydroxywarfarin with
7-, 8-, and 4′-hydroxywarfarin showing the lowest rates. Lastly,

Frontiers in Pharmacology | www.frontiersin.org

Steady-State Reduction Kinetics Varied
Among Hydroxywarfarins Compared to
Warfarin
Steady-state reactions in HLC150 were conducted to determine
mechanism and kinetics for reduction of hydroxywarfarin
isomers compared to the warfarin parent drug. Initial reaction
studies showed linearity in initial rates as a function of time and
protein concentration ensuring steady-state conditions (data not
shown). Figure 5 shows the resulting kinetic proﬁles from
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FIGURE 3 | Screening hydroxywarfarins for reduction by human liver cytosol. Initial reactions were carried out with 1.0 mg/ml protein human liver cytosol in 50 mM
potassium phosphate pH 7.4 with either (A) 100 or (B) 1,000 μM rac-warfarin (positive control) or rac-hydroxywarfarin. Reactions yielded alcohol 1 (minor metabolite,
light purple) and alcohol 2 (major metabolite, dark purple), although the reaction for rac-4′-hydroxywarfarin generated only alcohol 2.

those hydroxywarfarins (Figures 6A,B). The inhibition patterns
for the major alcohol were similar for both substrates with about
30% inhibition by H-FFA, 60% inhibition by QUE, and 70%
decrease in activity with H-INDO. Together, these results
implicate signiﬁcant contributions by Carbonyl reductase 1
(CBR1) and slightly less, though still signiﬁcant, contribution
by Aldo-Keto reductase Family 1 Member C3 (AKR1C3) toward
formation of alcohol 2 for both substrates. Similarly, H-INDO
and QUE decreased formation of the major alcohol from both
substrate reactions by 60–70% implicating a minor role for CBR1
in the pathways. For 7-hydroxywarfarin, there was also reaction
inhibition by 50% with H-FFA and 20% with L-FFA, while the
inhibition was less signiﬁcant inhibition for 10-hydroxywarfrin
reactions. These trends suggest AKR1C3 involvement in the
pathways is possibly more signiﬁcant for 7-hydroxywarfarin
than that for 10-hydroxywarfarin. Overall, inhibition results
indicated that 7- and 10-hydroxywarfarin reduction involves
mainly CBR1 with potential contributions from AKR1C3 as
reported for warfarin (Barnette, et al., 2017).

rac-hydroxywarfarin kinetic studies for minor (alcohol 1) and
major (alcohol 2) metabolites. For almost all alcohols, kinetic
proﬁles ﬁt best to the Michaelis-Menten mechanism with the
exception of alcohol 1 for rac-6-hydroxywarfarin, which did not
reach saturation by 1,000 μM, so initial rates in the linear range
up to 400 µM were ﬁt to a line yielding a slope to approximate
reaction speciﬁcity (Vmax/Km). The corresponding kinetic
parameters, Vmax and Km, and calculated speciﬁcities
(Vmax/Km) for reactions are reported in Table 2. Like
warfarin, the most efﬁcient reduction pathways led to alcohol
2 and in the case of rac-4′-hydroxywarfarin, the minor pathway
for alcohol 1 was not even measurable. In general, lower Vmax
values accompanied lower Km values suggesting substrate
recognition comes at the cost of substrate turnover. Overall
substrate recognition was moderate to very poor as reﬂected in
large Km values, and the maximal reaction rates (Vmax) varied
widely among the hydroxywarfarins and their alcohol
metabolites. Moreover, the relative speciﬁcities for the pairs of
alcohols for each hydroxywarfarin differed in magnitude. Taken
together, these ﬁndings indicated that introduction of the
hydroxyl group led to regioselectivity in metabolism but no
clear patterns, when compared to warfarin. For both alcohols,
rac-10-hydroxywarfarin had the highest speciﬁcities, and yet the
order of the less speciﬁc reactions depended on the location of the
hydroxyl group with rac-warfarin always the second most
efﬁcient.

Reductases Showed Chiral Preferences in
R- and S-7-Hydroxywarfarin Reductions
We sought insights on the impact of chirality toward reductase
selectivity and speciﬁcity during reactions. Studies with racemic
hydroxywarfarins yielded chromatographically resolved but
ambiguous
alcohol
metabolite
peaks.
Individual
hydroxywarfarin isomers are not commercially available;
however, we had previously synthesized R- and S-7hydroxywarfarin
for
studies
published
on
their
glucuronidation (Pugh, et al., 2018). In this case, we used
them to assess effects of chirality on the speciﬁcity of
hydroxywarfarin reduction. It was not possible to carry out
similar studies with 10-hydroxywarfarin due to the presence of
chiral centers at positions 9 and 10 (Jones et al., 2011) that pose a

Multiple Reductases Were Responsible for
Metabolism of 7- and 10-Hydroxywarfarin
Major oxidative metabolic pathways for warfarin yield primarily
7- and 10-hydroxywarfarin (Locatelli, et al., 2005; Pouncey, et al.,
2018) making them more relevant to in vivo clearance pathways,
and so we carried out phenotyping assays using reductase
inhibitors to identify enzymes responsible for the reduction of
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FIGURE 4 | Tandem Mass Spectrometry (LC-MS/MS) analysis conﬁrmed the predicted masses of the reduced hydroxywarfarin metabolites with reduced warfarin
as a control. Parent mass scans were conducted for the metabolites from cytosolic reduction reactions for (A) rac-warfarin, (B) rac-6-hydroxywarfarin, (C) rac-7hydroxywarfarin, (D) rac-8-hydroxywarfarin, (E) 10-hydroxywarfarin isomer mixture, and (F) rac-4′-hydroxywarfarin. Each panel includes the mass spectrum for alcohol
1 (top) and alcohol 2 (bottom). The colored line indicates the expected and observed 311 m/z for warfarin alcohol 1 (light purple) and alcohol 2 (dark purple) and the
expected and observed 327 m/z for hydroxywarfarin alcohol 1 (light purple) and alcohol 2 (dark purple), respectively.

signiﬁcant challenge for synthesis. As a baseline for 7hydroxywarfarin reactions, we carried out a reaction with
200 µM rac-7-hydroxywarfarin resolving the minor alcohol 1
and major alcohol 2 metabolites (Figure 7A). Those reactions

Frontiers in Pharmacology | www.frontiersin.org

contained 100 µM of R- and S-7-hydroxywarfarin, so we carried
out studies with the enantiomers at those concentrations
(Figure 7B). When compared to the rac-7-hydroxywarfarin
reaction, the reduction of R-7-hydroxywarfarin yielded a large,
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FIGURE 5 | Kinetic proﬁles for reduced metabolites formed from hydroxywarfarin metabolism by human liver cytosol. Steady-state reactions were carried out with
1.0 mg/ml protein human liver cytosol in 50 mM potassium phosphate pH 7.4 with varying concentrations of substrate. Plots of the initial rates for alcohol 1 (light purple)
and alcohol 2 (dark purple) as a function of hydroxywarfarin concentration were ﬁt to Michaelis-Menten mechanisms for reduction of (A) rac-6-hydroxywarfarin, (B) rac-7hydroxywarfarin, (C) rac-8-hydroxywarfarin, (D) 10-hydroxywarfarin isomer mixture (note difference in scaling versus other plots), and (E) rac-4′-hydroxywarfarin.
The corresponding Michaelis-Menten parameters for the best ﬁt curve are reported in Table 2. Error bars represent standard deviation of at least six replicates.

DISCUSSION

single peak with a retention time matching that for alcohol 2,
while S-7-hydroxywarfarin reduction led to a small peak
corresponding to the retention time for alcohol 1. Subsequent
kinetic studies yielded kinetic proﬁles conﬁrming those
observations (Figure 7C). Both data sets ﬁt best to the
Michaelis-Menten equation. For R-7-hydroxywarfarin, the
kinetic constants and corresponding 95% conﬁdence intervals
for alcohol 2 were Vmax 30 pmol/min/mg protein (29–31), Km
220 µM (190–260), and speciﬁcity 0.14 (Vmax/Km). For S-7hydroxywarfarin, the values were Vmax 2.4 pmol/min/mg
protein (1.9–3.2), Km 290 µM (160–550), and speciﬁcity 0.0083
(Vmax/Km). Taken together, these ﬁndings demonstrate that 7hydroxywarfarin undergoes enantioselective reduction favoring
to the R isomer and regiospeciﬁc product formation yielding a
single metabolite for either substrate.

Frontiers in Pharmacology | www.frontiersin.org

Hydroxywarfarin Reduction Depended on
Location of the Hydroxyl Group
We report the ﬁrst evidence for reductases catalyzing the conversion
of the C11 carbonyl of hydroxywarfarins into an alcohol as a novel
pathway for their elimination. As a rapid screen for metabolism, our
Rainbow metabolism model predicted that for the warfarin
metabolites, reduction would increase with closer proximity of
the hydroxyl group to the site of metabolism. That trend
correctly ranked 10-hydroxywarfarin, as the most likely to
undergo reduction followed by warfarin. Nevertheless, the pattern
did not hold true for the remaining hydroxywarfarins whether
considering the speciﬁcity for individual alcohol metabolites or
their combination. In fact, the experimental studies did not
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TABLE 2 | Michaelis-Menten kinetic parameters for reduction of warfarin and hydroxywarfarin isomersa.
Substrate

Kinetic constants

Alcohol 1

Alcohol 2

rac-warfarinb

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

4.8 (3.2–6.4)
330 (48–610)
0.015

78 (57–100)
710 (350–1,100)
0.11

rac-6-hydroxy-warfarin

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

—
—
0.0041c

57 (52–61)
510 (427–593)
0.11

rac-7-hydroxy-warfarin

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

0.78 (0.51–1.06)
390 (0.64–580)
0.0027

8.5 (8.1–9.0)
175 (140–210)
0.049

rac-8-hydroxy-warfarin

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

9.54 (7.5–11.6)
644 (370–920)
0.015

33 (30–36)
540 (420–560)
0.061

10-hydroxy-warfarin

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

31 (27–36)
500 (340–650)
0.063

156 (130–180)
600 (430–770)
0.26

rac-4′-hydroxy-warfarin

Vmax (pmol/min/mg)
Km (µM)
Vmax/Km

NA
NA
NA

18 (17–20)
180 (130–230)
0.10

a

Steady-state reactions were carried out with 1.0 mg/ml protein human liver cytosol in 50 mM potassium phosphate pH 7.4 with varying concentrations of substrate.
Barnette et al., 2017.
Kinetic proﬁle did not reach saturation by 1,000 μM, so initial rates in the linear range up to 400 µM were ﬁt to a line yielding a slope to approximate reaction speciﬁcity (Vmax/Km).

b
c

indicate any clear trends in the speciﬁcity of reduction for the rachydroxywarfarins or 10-hydroxywarfarin that varied up to six-fold
for overall speciﬁcity of reductions. rac-6-Hydroxywarfarin
demonstrated similar metabolic kinetics as rac-warfarin followed
by rac-8-hydroxywarfarin and lastly, rac-7-hydroxywarfarin.
Moreover, the speciﬁcity of reactions for alcohol 1 and 2 differed
among the hydroxywarfarin reactions. The collective ﬁndings
indicate the location of the hydroxyl group signiﬁcantly impacted
reduction selectivity among the hydroxywarfarins, as well as the
speciﬁcity for the resulting metabolites. Those effects may be due to
structural discriminations of individual reductases or the collection
of reductases present in cytosolic fractions.

First, 7-hydroxywarfarin reductions were enantioselective toward
the R substrate isomer. Second, reduction of either
hydroxywarfarins resulted in preferentially a single alcohol
despite two possibilities. This outcome indicated an
enantiospeciﬁc process likely reﬂecting the formation of S
alcohols based on warfarin reduction studies. The elution
order pattern for warfarin alcohols matched that observed for
7-hydroxywarfarin alcohols. Moreover, both warfarin and 7hydroxywarfarin are predominantly metabolized by CBR1 and
to a lesser extent AKR1C3 that favor formation of warfarin S
alcohols and presumably the same for 7-hydroxywarfarin. In
following, 7-hydroxywarfarin reduction likely generated 9S7,11S-dihydroxywarfarin (alcohol 1, minor metabolite) and
9R-7,11S-dihydroxywarfarin (alcohol 2, major metabolite).
These studies suggest that the hydroxyl group at position 7
did not alter chiral bias in metabolism. If this trend extends to
the other substrates in this study, then all hydroxywarfarin
reductions are enantioselective toward R substrates and
enantiospeciﬁc for S alcohol metabolites.

Reductases Carried Out Likely
Enantioselective and Enantiospeciﬁc
Hydroxywarfarin Metabolism
The reliance on racemic substrates for reactions masked
potentially important roles for chirality in metabolic ﬂux for
individual hydroxywarfarins to the respective alcohol
metabolites. For comparison, our previous work with warfarin
revealed signiﬁcant chiral bias in reactions (Barnette, et al., 2017).
CBR1 and AKR1C3 demonstrated a higher speciﬁcity toward
R-warfarin reduction and a preference for formation of S alcohols
regardless of substrate chirality (Barnette, et al., 2017; Malátková
and Wsól 2014). In following, reactions with rac-warfarin in the
literature (Barnette, et al., 2017; Alshogran, et al., 2014;
Malátkova, et al., 2016) then yielded predominantly a minor
metabolite (alcohol 1, 9S-11S-hydroxywarfarin) and a major
metabolite (alcohol 2, 9R-11S-hydroxywarfarin). This trend
may also apply to hydroxywarfarin reactions. We explored the
impact of chirality on 7-hydroxywarfarin reduction and observed
many similarities to warfarin reactions (Barnette, et al., 2017).

Frontiers in Pharmacology | www.frontiersin.org

10-Hydroxywarfarin Reduction May be a
Clinically Relevant Pathway Impacting
Anticoagulation Therapy
The reduction of 10-hydroxywarfarin is the only elimination
pathway that may have clinical signiﬁcance. By comparison,
reductive reactions for the other hydroxywarfarins were much
less efﬁcient. Moreover, 6-, 7-, 8- and 4′-hydroxywarfarins readily
undergo glucuronidation (Zielinska, et al., 2007; Bratton, et al.,
2012; Kim, et al., 2019; Pugh, et al., 2018) to yield glucuronides
excreted in the urine (Kaminsky and Zhang 1997; Miller, Jones,
et al., 2009). The effectiveness of those pathways presumably
explains the very low nanomolar levels of those hydroxywarfarins
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FIGURE 6 | Inhibitor phenotyping for 7- and 10-hydroxywarfarin carbonyl reduction reactions in human liver cytosol. Inhibitor reactions contained 1.0 mg/ml
protein human liver cytosol in 50 mM potassium phosphate pH 7.4 and 5% methanol with 250 μM substrate with and without reductase inhibitors for AKR1C3 and
CBR1 for (A) rac-7-hydroxywarfarin and (B) 10-hydroxywarfarin. The speciﬁcities of the inhibitors are indicated by the bars in which some inhibitors and conditions were
speciﬁc for either reductase while other conditions inhibited both reductases. Signiﬁcance was determined using one way ANOVA statistical test. Abbreviations are
as follows: L-FFA: low ﬂufenamic acid (2 μM); H-FFA: high ﬂufenamic acid (10 μM); L-INDO: low indomethacin (5 μM); H-INDO: high indomethacin (INDO, 180 μM); QUE:
quercetin (60 μM).

in patient plasma (Haque, et al., 2014; Pouncey, et al., 2018),
including S-7-hydroxywarfarin, a metabolite of the main pathway
for S-warfarin elimination (Krishna Kumar et al., 2013; Rettie,
et al., 1992). In contrast, 10-hydroxywarfarin is not detectable in
patient urine (Miller, Jones, et al., 2009) and accumulates
collectively almost up to micromolar levels in patient plasma
following warfarin maintenance dosing (Haque, et al., 2014;
Pouncey, et al., 2018). The resulting 10-hydroxywarfarin levels
are sufﬁcient to potentate anticoagulation directly by inhibiting
VKORC1 (Haque, et al., 2014) and indirectly by inhibiting
S-warfarin metabolism (Jones, et al., 2010c). Reported warfarin
interactions with rifampicin (Kendan Alexander, 2014) and

Frontiers in Pharmacology | www.frontiersin.org

possibly nafcillin (Rulcova, et al., 2010) are consistent with
those mechanisms. Both drugs induce CYP3A4 and thus, its
role in metabolizing warfarin into 10-hydroxywarfarin.
Clinically, the drug combinations decreased the R-warfarin
half-life and increased the S-warfarin half-life resulting in
warfarin sensitivity and a higher risk for bleeding. The
reduction of 10-hydroxywarfarin provides a counterbalance to
those outcomes. The metabolic pathway would alleviate 10hydroxywarfarin inhibition of CYP2C9 metabolism of the
pharmacologically potent S-warfarin and facilitate elimination
of 10-hydroxywarfarin contributions to anticoagulation. In the
clinic, the importance of reductases on those patient outcomes
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FIGURE 7 | Enantioselective and enantiospeciﬁc metabolism of R- and S-7-hydroxywarfarin. An exploration of the impact of chirality on hydroxywarfarin reduction
carried out with chromatographically puriﬁed 7-hydroxywarfarin enantiomers. (A) As a baseline for comparison, chromatographic analysis of 200 μM rac-7hydroxywarfarin reduction (100 μM of each enantiomer) using 1.0 mg/ml protein human liver cytosol in 50 mM potassium phosphate pH 7.4 in the absence or presence
of NADPH. (B) Chromatographic analysis of the reduction of 100 μM of either R-7-hydroxywarfarin (red) or S-7-hydroxywarfarin (blue) under the same reaction
conditions. (C) Steady-state kinetics were carried out with the same reaction conditions but varying concentrations of substrate. Plots of initial rates as a function of 7hydroxywarfarin concentration were ﬁt to the Michaelis-Menten mechanism for R-7-hydroxywarfarin (red, alcohol 2) or S-7-hydroxywarfarin (blue, alcohol 1). The
corresponding kinetic constants are reported in Reductases Showed Chiral Preferences in R- and S-7-Hydroxywarfarin Reductions under Results.

will depend on clinical factors like genetics, personal habits, and
environmental factors that inﬂuence CBR1 and possibly AKR1C3
activities toward 10-hydroxywarfarin reduction (Kassner, et al.,
2008).

possible by using our prior work with warfarin and alcohol
standards along with exploratory studies with R- and S-7hydroxywarfarin. Our results showed enantiospeciﬁcity and
enantioselectivity of 7-hydroxywarfarin reduction that
matched the general trend observed previously for warfarin
reduction. Based on this ﬁnding, we predicted a similar trend
occurs with the other hydroxywarfarin isomers.

Limitations
The challenges in handling chirality in reactions were the main
limitations of this work. The Rainbow Model lacked chiral
descriptors for substrates and its application to possible
metabolites. Additionally, model outputs were qualitative
predictions for likelihood of a reaction to occur that did not
scale to quantitative experimental kinetic mechanisms and
constants. Consequently, we compared reaction speciﬁcities
(Vmax/Km) as an approximation of model predictions for
reactions to occur. The consistency of modeling and
experimental results for the most efﬁcient reactions but not
the others may indicate the scaling limitations of model
predictions to experimental data and/or performance of the
model itself. Retraining of the model with larger, more diverse
sets of reduction reactions would aid in resolving performance
issues. Lastly, experimental studies relied on racemic
substrates and inference for quantitating mixtures of
alcohol isomers due to the absence of pure, authentic
reagents. Nevertheless, interpretation of our results was

Frontiers in Pharmacology | www.frontiersin.org

Concluding Remarks
Coumadin (rac-warfarin) is a highly efﬁcacious drug that poses
challenges to adequate dosing due to a narrow therapeutic range
and sometimes unpredictable responses in patients. Critical
determinants of that uncertainty are gaps in our understanding
about how metabolism impacts the potency and levels of
pharmacologically active parent drugs and metabolites. The
studies reported herein revealed a previously unknown reduction
pathway for the elimination of 10-hydroxywarfarin that may play a
role in the uncertainty in patient response to warfarin therapy.
Knowledge of pathways leading to 10-hydroxywarfarin by
CYP3A4 and elimination by reductases provides a more complete
picture of the metabolic ﬂux for this metabolite. The resulting 10hydroxywarfarin levels would then mediate its direct and indirect
effects on the anticoagulant response that would be the foundation for
important follow up clinical studies based on this research.
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